TD Cowen analyst Joseph Thome downgraded Evelo Biosciences to Market Perform from Outperform without a price target.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EVLO:
- Horizon Technology downgraded to Sell from Neutral at Compass Point
- Evelo announces primary endpoint was not achieved in Phase 2 study of EDP2939
- Evelo Biosciences Announces Top-Line Results From its Phase 2 Clinical Study with EDP2939 in Moderate Psoriasis
- Compass Point ups Horizon Technology to Neutral on positive 12-month return
- Biotech Alert: Searches spiking for these stocks today